September 14, 2023
On September 11, 2023, Bacardi Limited (“Bacardi”), the largest privately held international spirits company in the world, announced the completion of a transaction that makes the family‑owned company the sole owner of ILEGAL Mezcal®, a leading super premium artisanal mezcal. Cravath is representing Bacardi in connection with the transaction.
The Cravath team is led by partner Ting S. Chen and includes associates Joseph A. Marshall, Nicole M. Gould and J. Elizabeth Allan on M&A matters; partners Lauren Angelilli and Andrew T. Davis and associate Emily R. Eskin on tax matters; partner Eric W. Hilfers, of counsel Sarah W. Colangelo, senior attorney Arian Mossanenzadeh and practice area attorney Courtnii Lamar on executive compensation and benefits matters; partners George E. Zobitz and Paul H. Zumbro and associate Philip Iacovou on financial restructuring matters; partner Sasha Rosenthal-Larrea and associates Carys J. Webb and Joanne Dynak on intellectual property matters; and partner Matthew Morreale and associate Star S. Gulant on environmental matters.
Deals & Cases
September 13, 2023
On September 12, 2023, J.D. Power, a global leader in data analytics, announced a definitive agreement to acquire Autovista Group, a leading pan‑European and Australian automotive data, analytics and industry insights provider. Cravath is representing European alternative asset management firm Hayfin Capital Management, which currently owns Autovista Group, as U.S. counsel in connection with the transaction.
Deals & Cases
September 12, 2023
On September 12, 2023, the Boards of WestRock and Smurfit Kappa announced the signing of a definitive transaction agreement to create Smurfit WestRock, a global leader in sustainable packaging. Together, Smurfit Kappa and WestRock generated combined last twelve months’ adjusted annual revenue of approximately $34 billion as of June 30, 2023. Cravath is representing WestRock in connection with the transaction.
Deals & Cases
June 30, 2023
On June 30, 2023, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, managed by DRI Capital Inc., announced that it has purchased a royalty interest in the worldwide net sales of Orserdu™, the first approved targeted therapy used in the treatment of postmenopausal women or adult men with advanced or metastatic breast cancer who have experienced disease progression despite prior endocrine therapy, from Eisai Co., Ltd. for $85 million. In addition to the running royalties, DRI Healthcare Trust is also entitled to receive milestones based on the achievement of regulatory and sales performance thresholds. Cravath represented DRI Capital Inc. in connection with the transaction.
Deals & Cases
April 27, 2023
On April 27, 2023, Deutsche Börse AG, an international exchange organization and market infrastructure provider, and SimCorp A/S, which offers a front‑to‑back investment management platform and ecosystem used by asset owners and managers, entered into a binding agreement pursuant to which Deutsche Börse AG will make an all cash voluntary recommended public takeover offer to acquire all the shares (except treasury shares) in SimCorp A/S at a price of DKK 735.0 per share, adjusted for any dividends or other distributions paid by SimCorp A/S prior to completion of the offer, valuing the entire issued capital of SimCorp A/S at €3.9 billion. In parallel to the takeover of SimCorp A/S, Deutsche Börse AG intends to combine its existing data & analytics subsidiaries Qontigo and ISS under one leadership. Upon completion of the offer, the intended combination of Qontigo/ISS and SimCorp A/S will be grouped within a newly created Investment Management Solutions segment. Cravath is representing Deutsche Börse AG as U.S. counsel in connection with the transactions.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.